Incyte
NEWS
Companies have already begun their announcements of new clinical studies for various treatment settings in preparation for ASCO 2021.
Please check out the biopharma industry’s COVID-19 stories that are trending for April 13, 2021.
It was a relatively quiet week for clinical trial announcements, but there were a few standouts. Read on for more.
Eli Lilly and Company and Incyte announced today that their Phase III COV-BARRIER study of Olumiant (baricitinib) plus standard of care (SoC) compared to placebo plus SoC failed to hit statistical significance against COVID-19 for its primary endpoint.
The action data was extended by the agency to provide more time to review new data analyses submitted by Lilly, per information requests made by the FDA.
The topline data from the BRAVE-AA2 study in 546 adults showed both 2 mg and 4 mg doses of Olumiant regrew hair in adult patients with more than 50% scalp hair loss, compared with placebo.
Many companies appear to be getting their clinical trial news updated ahead of the holidays. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 15, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 24, 2020.
JOBS
IN THE PRESS